Rishi Pal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rishi Pal has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Rajendra Nath
Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow, Uttar Pradesh, India
10 shared publications- Prafulla Chandra Tiwari
Department of Pharmacology and Therapeutics King George's Medical University Lucknow Uttar Pradesh India
9 shared publications Manju J. Chaudhary
Government Medical College
7 shared publications- Rajendra Nath
Department of Pharmacology, King George’s Medical University, Lucknow, Uttar Pradesh, India
6 shared publications - Manju Jyoti Chaudhary
Department of Physiology Government Medical College Kannauj Uttar Pradesh India
4 shared publications Prafulla Chandra Tiwari
King George’s Medical University
4 shared publications
Latest Publications
- 1 November 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1874
Targeting RIPK1-NF-κB crosstalk: A novel perspective on necroptosis in Alzheimer’s Disease
- 1 November 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1874
Targeting RIPK1-NF-κB crosstalk: A novel perspective on necroptosis in Alzheimer’s Disease
- Open Access
- 1 October 2026
- Published by Springer Nature in Cureus
- Vol. 18 (10)
The Emerging Role of α-Synuclein Strains in Parkinson’s Disease: From Molecular Pathology to Clinical Phenotypes
Progressive loss of dopaminergic neurons and the formation of α-synuclein aggregates are hallmarks of Parkinson’s disease. Biochemical, biophysical, cellular, animal, and clinical studies provide increasing evidence that α-synuclein is a highly “heterogeneous protein” that may exist in nature in different conformational states or “strains.” The various strains differ biochemically and biophysically, elicit different seeding activities in cell culture assays, and have distinct pathological and cellular effects. The ability of different α-synuclein strains to seed and propagate themselves through host cells could explain the ability of misfolded α-synuclein to act as a prion-like agent, spread from neuron to neuron, and cause disease. Notably, different α-synuclein strains can have different abilities to propagate in cell culture and animal models of Parkinson's disease. Moreover, specific α-synuclein strains may induce similar motor, cognitive, psychiatric, and autonomic signs and symptoms of human Parkinson's disease. The heterogeneity of α-synuclein strains may, therefore, contribute to the variety of clinical presentations of the disease. However, the clinical associations of specific α-synuclein strains are mostly indirect and based on correlational studies. Thus, α-synuclein strains might serve as useful biomarkers of disease prognosis and stratification, although the evidence for their role in Parkinson's disease is still limited. At the same time, there are significant methodological limitations to current approaches used for characterizing α-synuclein strains, and much work remains to be done before α-synuclein strains can be reliably used to predict patient outcomes.
- 1 October 2026
- Published by Springer Nature in Cureus
- Vol. 18 (10)
Open AccessThe Emerging Role of α-Synuclein Strains in Parkinson’s Disease: From Molecular Pathology to Clinical Phenotypes
Progressive loss of dopaminergic neurons and the formation of α-synuclein aggregates are hallmarks of Parkinson’s disease. Biochemical, biophysical, cellular, animal, and clinical studies provide increasing evidence that α-synuclein is a highly “heterogeneous protein” that may exist in nature in different conformational states or “strains.” The various strains differ biochemically and biophysically, elicit different seeding activities in cell culture assays, and have distinct pathological and cellular effects. The ability of different α-synuclein strains to seed and propagate themselves through host cells could explain the ability of misfolded α-synuclein to act as a prion-like agent, spread from neuron to neuron, and cause disease. Notably, different α-synuclein strains can have different abilities to propagate in cell culture and animal models of Parkinson's disease. Moreover, specific α-synuclein strains may induce similar motor, cognitive, psychiatric, and autonomic signs and symptoms of human Parkinson's disease. The heterogeneity of α-synuclein strains may, therefore, contribute to the variety of clinical presentations of the disease. However, the clinical associations of specific α-synuclein strains are mostly indirect and based on correlational studies. Thus, α-synuclein strains might serve as useful biomarkers of disease prognosis and stratification, although the evidence for their role in Parkinson's disease is still limited. At the same time, there are significant methodological limitations to current approaches used for characterizing α-synuclein strains, and much work remains to be done before α-synuclein strains can be reliably used to predict patient outcomes.
- Open Access
- 16 March 2026
- Published by Scientific Scholar in Indian Journal of Physiology and Pharmacology
- p. 1-7
Protective effects of phosphodiesterase-5 inhibitor (Tadalafil) in stress-induced anxiety, depression and gastric ulceration in rats
Objectives: Prolonged stress is known to precipitate neuropsychiatric and gastrointestinal disorders through disruption of the hypothalamic-pituitary-adrenal (HPA) axis, activation of neuroinflammatory pathways and oxidative damage to the gastric mucosa. Phosphodiesterase-5 (PDE5) inhibitors, including tadalafil, facilitate cyclic guanosine monophosphate-dependent vasodilation, enhance neuroplastic mechanisms and exert anti-inflammatory effects. The role of PDE5 inhibitors in stress modulation and gastric ulceration is not well understood. Therefore, the present study assessed the potential anxiolytic, antidepressant-like effect and gastroprotective actions of tadalafil in restraint stress (RS)-induced changes. Materials and Methods: Forty-eight adult Wistar rats (either sex) were randomised into eight groups ( n = 6): normal control, -stress (RS, 4 h daily × 7 days), RS + diazepam (2 mg/kg, i.p.), RS + imipramine (30 mg/kg, p.o.), RS + ranitidine (150 mg/kg, p.o.) and RS + tadalafil (2, 5 or 10 mg/kg, p.o.). Behaviour was assessed using the Elevated Plus Maze and Open-Field Test. Gastric ulcer index (UI), serum corticosterone, brain tumour necrosis factor α (TNF-α) and interleukin 1β (IL-1β) were quantified by the enzyme-linked immunosorbent assay technique. Dose–response trends were analysed by linear regression. Results: RS significantly increased anxiety index (0.90 ± 0.02 vs. 0.80 ± 0.01; P < 0.001), reduced locomotor activity (crossings: 16.0 ± 5.9 vs. 43.5 ± 4.4; P < 0.001) and raised UI (7.24 ± 0.38 vs. 2.09 ± 0.25 mm 2 ; P < 0.0001). Tadalafil (10 mg/kg) reversed the anxiety index to values comparable with those of stress (0.90 ± 0.02 vs. 0.74 ± 0.02; P < 0.05) and reduced UI to 2.32 ± 0.21 mm 2 ( P < 0.001), findings comparable with those of diazepam and ranitidine. RS caused an increase in TNF-α (15.27 ± 1.66 pg/mL) and IL-1β (16.09 ± 2.71 pg/mL) ( P < 0.001). Treatment with tadalafil reduced these cytokine levels in a dose-dependent manner (TNF-α = −0.223, IL-1β = −0.376); tadalafil (10 mg/kg) reduced serum corticosterone levels compared with the stress group (10.88 ± 1.76 vs. 16.61 ± 1.09 ng/mL, P < 0.05). Linear regression analysis demonstrated a significant inverse dose–response relationship for both the anxiety index (β = −0.0067, R 2 = 0.576, P = 0.0003) and UI (β = −0.0733, R 2 = 0.408, P = 0.0043). Conclusion: Tadalafil exhibits notable anxiolytic and gastroprotective activity in restraint-stressed rats, highlighting PDE5 inhibition as a potential multi-target therapeutic approach for stress-induced neuropsychiatric and gastrointestinal disorders.
- 16 March 2026
- Published by Scientific Scholar in Indian Journal of Physiology and Pharmacology
- p. 1-7
Open AccessProtective effects of phosphodiesterase-5 inhibitor (Tadalafil) in stress-induced anxiety, depression and gastric ulceration in rats
Objectives: Prolonged stress is known to precipitate neuropsychiatric and gastrointestinal disorders through disruption of the hypothalamic-pituitary-adrenal (HPA) axis, activation of neuroinflammatory pathways and oxidative damage to the gastric mucosa. Phosphodiesterase-5 (PDE5) inhibitors, including tadalafil, facilitate cyclic guanosine monophosphate-dependent vasodilation, enhance neuroplastic mechanisms and exert anti-inflammatory effects. The role of PDE5 inhibitors in stress modulation and gastric ulceration is not well understood. Therefore, the present study assessed the potential anxiolytic, antidepressant-like effect and gastroprotective actions of tadalafil in restraint stress (RS)-induced changes. Materials and Methods: Forty-eight adult Wistar rats (either sex) were randomised into eight groups ( n = 6): normal control, -stress (RS, 4 h daily × 7 days), RS + diazepam (2 mg/kg, i.p.), RS + imipramine (30 mg/kg, p.o.), RS + ranitidine (150 mg/kg, p.o.) and RS + tadalafil (2, 5 or 10 mg/kg, p.o.). Behaviour was assessed using the Elevated Plus Maze and Open-Field Test. Gastric ulcer index (UI), serum corticosterone, brain tumour necrosis factor α (TNF-α) and interleukin 1β (IL-1β) were quantified by the enzyme-linked immunosorbent assay technique. Dose–response trends were analysed by linear regression. Results: RS significantly increased anxiety index (0.90 ± 0.02 vs. 0.80 ± 0.01; P < 0.001), reduced locomotor activity (crossings: 16.0 ± 5.9 vs. 43.5 ± 4.4; P < 0.001) and raised UI (7.24 ± 0.38 vs. 2.09 ± 0.25 mm 2 ; P < 0.0001). Tadalafil (10 mg/kg) reversed the anxiety index to values comparable with those of stress (0.90 ± 0.02 vs. 0.74 ± 0.02; P < 0.05) and reduced UI to 2.32 ± 0.21 mm 2 ( P < 0.001), findings comparable with those of diazepam and ranitidine. RS caused an increase in TNF-α (15.27 ± 1.66 pg/mL) and IL-1β (16.09 ± 2.71 pg/mL) ( P < 0.001). Treatment with tadalafil reduced these cytokine levels in a dose-dependent manner (TNF-α = −0.223, IL-1β = −0.376); tadalafil (10 mg/kg) reduced serum corticosterone levels compared with the stress group (10.88 ± 1.76 vs. 16.61 ± 1.09 ng/mL, P < 0.05). Linear regression analysis demonstrated a significant inverse dose–response relationship for both the anxiety index (β = −0.0067, R 2 = 0.576, P = 0.0003) and UI (β = −0.0733, R 2 = 0.408, P = 0.0043). Conclusion: Tadalafil exhibits notable anxiolytic and gastroprotective activity in restraint-stressed rats, highlighting PDE5 inhibition as a potential multi-target therapeutic approach for stress-induced neuropsychiatric and gastrointestinal disorders.
- 2 January 2026
- Published by Springer Nature
- p. 1-24
History and Evolution of CAR T-Cell Therapy
- 5 March 2025
- Published by Elsevier
- Vol. 198, 221-250
In vivo cancer modeling using mouse models
- Top Cited Papers
- 15 September 2023
- Published by Wiley in Drug Development Research
- Vol. 84 (8) , 1652-1663
Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges
By harnessing artificial intelligence (AI) algorithms and machine learning techniques, the entire drug discovery process stands to undergo a profound transformation, offering a myriad of advantages. Foremost among these is the ability of AI to conduct swift and efficient screenings of expansive compound libraries, significantly augmenting the identification of potential drug candidates. Moreover, AI algorithms can prove instrumental in predicting the efficacy and safety profiles of candidate compounds, thus endowing invaluable insights and reducing reliance on extensive preclinical and clinical testing. This predictive capacity of AI has the potential to streamline the drug development pipeline and enhance the success rate of clinical trials, ultimately resulting in the emergence of more efficacious and safer therapeutic agents. However, the deployment of AI in drug discovery introduces certain challenges that warrant attention. A primary hurdle entails the imperative acquisition of high‐quality and diverse data. Furthermore, ensuring the interpretability of AI models assumes critical importance in securing regulatory endorsement and cultivating trust within scientific and medical communities. Addressing ethical considerations, including data privacy and mitigating bias, represents an additional momentous challenge, requiring assiduous navigation. In this review, we provide an intricate and comprehensive overview of the multifaceted challenges intrinsic to conventional drug development paradigms, while simultaneously interrogating the efficacy of AI in effectively surmounting these formidable obstacles.
- 15 September 2023
- Published by Wiley in Drug Development Research
- Vol. 84 (8) , 1652-1663
Top Cited PapersArtificial intelligence revolutionizing drug development: Exploring opportunities and challenges
By harnessing artificial intelligence (AI) algorithms and machine learning techniques, the entire drug discovery process stands to undergo a profound transformation, offering a myriad of advantages. Foremost among these is the ability of AI to conduct swift and efficient screenings of expansive compound libraries, significantly augmenting the identification of potential drug candidates. Moreover, AI algorithms can prove instrumental in predicting the efficacy and safety profiles of candidate compounds, thus endowing invaluable insights and reducing reliance on extensive preclinical and clinical testing. This predictive capacity of AI has the potential to streamline the drug development pipeline and enhance the success rate of clinical trials, ultimately resulting in the emergence of more efficacious and safer therapeutic agents. However, the deployment of AI in drug discovery introduces certain challenges that warrant attention. A primary hurdle entails the imperative acquisition of high‐quality and diverse data. Furthermore, ensuring the interpretability of AI models assumes critical importance in securing regulatory endorsement and cultivating trust within scientific and medical communities. Addressing ethical considerations, including data privacy and mitigating bias, represents an additional momentous challenge, requiring assiduous navigation. In this review, we provide an intricate and comprehensive overview of the multifaceted challenges intrinsic to conventional drug development paradigms, while simultaneously interrogating the efficacy of AI in effectively surmounting these formidable obstacles.
- Open Access
- 27 August 2023
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 31 (4) , 265-276
Modulation of Autophagy and Nitric Oxide Signaling via Glycyrrhizic Acid and 7-Nitroindazole in MPTP-induced Parkinson’s Disease Model
Background: Parkinson’s disease (PD) is characterized by dopaminergic (DA) neuron loss, Lewy body build-up, and motor dysfunction. One of the primary pathogenic mechanisms of PD development is autophagy dysfunction and nitric oxide-mediated neurotoxicity. Purpose: The current study focuses on autophagy and nitric oxide (NO) signaling roles in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated PD mice and their protection by their modulators. Method: BALB/c mice were administered MPTP (30 mg/kg/i.p/day) for five consecutive days in order to create a PD model. Following MPTP poisoning, the doses of GA (16.8 mg/kg/day/i.p.), 7-nitroindazole (7-NI) (10 mg/kg/day/i.p.), and their combination were administered once daily for 14 days. Animals were observed for behavioral and locomotor changes, biochemical examination, inflammatory mediators, and analysis of molecular markers. Results: GA, 7-NI alone significantly reduced MPTP-induced locomotor, behavioral, and oxidative damage. Additionally, in MPTP-intoxicated animals, 7-NI and GA had protective effects on dopamine levels, TH positive DA neurons, inflammatory cytokines interleukin 1β (IL-1β), tumor necrosis factor-alpha (TNF-α), nuclear factor-kappa B (NF-κB), and cyclooxygenase-2 (Cox-2) concentration. Furthermore, GA increases LC3BII expression, which in turn increases autophagy. It also decreases total NO content, and a significant response of 7-NI demonstrates their interaction, which is neuroprotective. Conclusion: Present research suggests that dysregulation of autophagy and NO-mediated neuroinflammation are involved in the pathogenesis and progression of MPTP-induced PD. The use of two pharmacotherapeutics, GA and 7-NI, respectively, significantly reduces MPTP-induced PD distortions and their interaction enhances the overall protective effect, suggesting that these pharmacological agents may be used for the treatment of PD.
- 27 August 2023
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 31 (4) , 265-276
Open AccessModulation of Autophagy and Nitric Oxide Signaling via Glycyrrhizic Acid and 7-Nitroindazole in MPTP-induced Parkinson’s Disease Model
Background: Parkinson’s disease (PD) is characterized by dopaminergic (DA) neuron loss, Lewy body build-up, and motor dysfunction. One of the primary pathogenic mechanisms of PD development is autophagy dysfunction and nitric oxide-mediated neurotoxicity. Purpose: The current study focuses on autophagy and nitric oxide (NO) signaling roles in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated PD mice and their protection by their modulators. Method: BALB/c mice were administered MPTP (30 mg/kg/i.p/day) for five consecutive days in order to create a PD model. Following MPTP poisoning, the doses of GA (16.8 mg/kg/day/i.p.), 7-nitroindazole (7-NI) (10 mg/kg/day/i.p.), and their combination were administered once daily for 14 days. Animals were observed for behavioral and locomotor changes, biochemical examination, inflammatory mediators, and analysis of molecular markers. Results: GA, 7-NI alone significantly reduced MPTP-induced locomotor, behavioral, and oxidative damage. Additionally, in MPTP-intoxicated animals, 7-NI and GA had protective effects on dopamine levels, TH positive DA neurons, inflammatory cytokines interleukin 1β (IL-1β), tumor necrosis factor-alpha (TNF-α), nuclear factor-kappa B (NF-κB), and cyclooxygenase-2 (Cox-2) concentration. Furthermore, GA increases LC3BII expression, which in turn increases autophagy. It also decreases total NO content, and a significant response of 7-NI demonstrates their interaction, which is neuroprotective. Conclusion: Present research suggests that dysregulation of autophagy and NO-mediated neuroinflammation are involved in the pathogenesis and progression of MPTP-induced PD. The use of two pharmacotherapeutics, GA and 7-NI, respectively, significantly reduces MPTP-induced PD distortions and their interaction enhances the overall protective effect, suggesting that these pharmacological agents may be used for the treatment of PD.
- Open Access
- 23 August 2023
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 31 (3) , 186-203
Role of Nitric Oxide Modulators in Neuroprotective Effects of Mangiferin in 6-Hydroxydopamine-induced Parkinson’s Disease in Rats
Background: Parkinson’s disease (PD) is typified by inflammation of dopaminergic neurons leading to the release of various inflammatory mediators. These mediators activate the transcription factor NF-κB, which in turn activates inducible nitric oxide synthase (iNOS), leading to increased inflammation. Purpose: This study was intended to study the effect of combination of mangiferin, a specific inhibitor of NF-κB with low-dose nitric oxide (NO) modulators. Methods: A total of eight Wistar rats weighing 200–250 g were used in each group. Stereotactic surgery was performed to induce 6-hydroxydopamine (6-OHDA) lesions. The treatment period extended from day 14 to day 42, during which time behavioral tests were performed to evaluate the effects of mangiferin and its combination with NO modulators. On day 42, the brains of the rats were removed for biochemical and molecular analyzes. Results: Mangiferin significantly improved locomotor activity and decreased inflammatory chemokines levels in rats with 6-OHDA lesions. Mangiferin therapy decreased myeloperoxidase (MPO) levels and reduced oxidative stress. In particular, caspase-3, caspase-9 and COX-2 activities were significantly reduced after the mangiferin treatment. A combination of 45-µg mangiferin and 10-mg/kg L-NAME showed the greatest improvement in locomotor, behavioral, biochemical, and molecular parameters impaired by 6-OHDA. Conclusion: In this study, mangiferin was found to protect rats with 6-OHDA lesions by inhibiting inflammation causing chemokines such as TNF-α and IL-6. Besides, the grouping of iNOS inhibitor L-NAME at a dose of 10 mg/kg with 45-µg mangiferin enhanced the anti-inflammatory and anti-Parkinsonian activity of mangiferin. Consequently, the combination therapy of mangiferin and L-NAME is promising for the treatment of PD. However, clinical trials will be required to evaluate the efficacy of this combination therapy in humans.
- 23 August 2023
- Published by SAGE Publications in Annals of Neurosciences
- Vol. 31 (3) , 186-203
Open AccessRole of Nitric Oxide Modulators in Neuroprotective Effects of Mangiferin in 6-Hydroxydopamine-induced Parkinson’s Disease in Rats
Background: Parkinson’s disease (PD) is typified by inflammation of dopaminergic neurons leading to the release of various inflammatory mediators. These mediators activate the transcription factor NF-κB, which in turn activates inducible nitric oxide synthase (iNOS), leading to increased inflammation. Purpose: This study was intended to study the effect of combination of mangiferin, a specific inhibitor of NF-κB with low-dose nitric oxide (NO) modulators. Methods: A total of eight Wistar rats weighing 200–250 g were used in each group. Stereotactic surgery was performed to induce 6-hydroxydopamine (6-OHDA) lesions. The treatment period extended from day 14 to day 42, during which time behavioral tests were performed to evaluate the effects of mangiferin and its combination with NO modulators. On day 42, the brains of the rats were removed for biochemical and molecular analyzes. Results: Mangiferin significantly improved locomotor activity and decreased inflammatory chemokines levels in rats with 6-OHDA lesions. Mangiferin therapy decreased myeloperoxidase (MPO) levels and reduced oxidative stress. In particular, caspase-3, caspase-9 and COX-2 activities were significantly reduced after the mangiferin treatment. A combination of 45-µg mangiferin and 10-mg/kg L-NAME showed the greatest improvement in locomotor, behavioral, biochemical, and molecular parameters impaired by 6-OHDA. Conclusion: In this study, mangiferin was found to protect rats with 6-OHDA lesions by inhibiting inflammation causing chemokines such as TNF-α and IL-6. Besides, the grouping of iNOS inhibitor L-NAME at a dose of 10 mg/kg with 45-µg mangiferin enhanced the anti-inflammatory and anti-Parkinsonian activity of mangiferin. Consequently, the combination therapy of mangiferin and L-NAME is promising for the treatment of PD. However, clinical trials will be required to evaluate the efficacy of this combination therapy in humans.
- Open Access
- 11 May 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (5) , 1422
Effect of Curcumin and Coenzyme Q10 Alone and in Combination on Learning and Memory in an Animal Model of Alzheimer’s Disease
The most frequent neurodegenerative illness among senior people and the main cause of dementia is Alzheimer’s disease. The present dementia medications available only help with the symptoms of cognitive deficits and have several negative effects. The current study’s goal is to assess the effects of curcumin and coenzyme Q10, two herbal medicines, both separately and in combination, on learning and memory before comparing them to the industry standard drug. A total of 42 adult healthy Wistar rats were used in our study. In this experiment, rats were given daily doses of 2.5 mg/kg of body weight of scopolamine hydrobromide for 7 days to induce Alzheimer’s disease. On the eighth day, behavioural testing was conducted. Following testing, scopolamine and the test medications were given daily for the following 21 days. On days 29 and 30, behavioural testing was conducted once more, and then animals were slaughtered. Brain homogenate was produced for the estimation of molecular and biochemical markers. Curcumin has demonstrated a dose–response relationship, with a higher dose (200 mg/kg b.w. p.o.) being more effective than a lower dose (100 mg/kg b.w. p.o.). Similar to the greater dose of curcumin, coenzyme Q10 (200 mg/kg b.w. p.o.) has also been found to improve memory and learning. Higher doses of curcumin and coenzyme Q10 had more pronounced and meaningful effects. Acetylcholinesterase and TNF levels increased in scopolamine-induced memory impairment, but these effects were restored by the test medications, and improved by the combined therapy. These outcomes are comparable to those of the common medication memantine. As a result, we may infer from our results that curcumin at higher doses and its combination with coenzyme Q10 (200 mg/kg b.w. p.o.) have a significant impact on cognitive impairment in animal models of Alzheimer’s disease and can be utilised alone or as an add-on therapy for the condition.
- 11 May 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (5) , 1422
Open AccessEffect of Curcumin and Coenzyme Q10 Alone and in Combination on Learning and Memory in an Animal Model of Alzheimer’s Disease
The most frequent neurodegenerative illness among senior people and the main cause of dementia is Alzheimer’s disease. The present dementia medications available only help with the symptoms of cognitive deficits and have several negative effects. The current study’s goal is to assess the effects of curcumin and coenzyme Q10, two herbal medicines, both separately and in combination, on learning and memory before comparing them to the industry standard drug. A total of 42 adult healthy Wistar rats were used in our study. In this experiment, rats were given daily doses of 2.5 mg/kg of body weight of scopolamine hydrobromide for 7 days to induce Alzheimer’s disease. On the eighth day, behavioural testing was conducted. Following testing, scopolamine and the test medications were given daily for the following 21 days. On days 29 and 30, behavioural testing was conducted once more, and then animals were slaughtered. Brain homogenate was produced for the estimation of molecular and biochemical markers. Curcumin has demonstrated a dose–response relationship, with a higher dose (200 mg/kg b.w. p.o.) being more effective than a lower dose (100 mg/kg b.w. p.o.). Similar to the greater dose of curcumin, coenzyme Q10 (200 mg/kg b.w. p.o.) has also been found to improve memory and learning. Higher doses of curcumin and coenzyme Q10 had more pronounced and meaningful effects. Acetylcholinesterase and TNF levels increased in scopolamine-induced memory impairment, but these effects were restored by the test medications, and improved by the combined therapy. These outcomes are comparable to those of the common medication memantine. As a result, we may infer from our results that curcumin at higher doses and its combination with coenzyme Q10 (200 mg/kg b.w. p.o.) have a significant impact on cognitive impairment in animal models of Alzheimer’s disease and can be utilised alone or as an add-on therapy for the condition.
- 27 February 2023
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 37 (4) , 794-806
Anti‐oxidative and anti‐neuroinflammatory role of Necrostatin‐1s and docosahexaenoic acid in RIP‐1‐mediated neurotoxicity in MPTP‐induced Parkinson's disease model
Parkinson's disease (PD) is a neuromuscular ailment that affects people in their later years and causes both motor and non‐motor deficits. Receptor‐interacting protein‐1 (RIP‐1) is a critical participant in necroptotic cell death, possibly through an oxidant–antioxidant imbalance and cytokine cascade activation in PD pathogenesis. The present study examined the role of RIP‐1‐mediated necroptosis and neuroinflammation in the MPTP‐induced PD mouse model, as well as their protection by Necrostatin‐1s (an RIP signalling inhibitor), antioxidant DHA and their functional interaction. BALB/c mice were given acute MPTP therapy (4 injections of 15 mg/kg i.p. at 2‐h intervals) on day 1. After MPTP intoxication, Necrostatin‐1s (Nec‐1s; 8 mg/kg/day, i.p.) and DHA (300 mg/kg/day, p.o.) treatments were given once daily for 7 days. The Nec‐1s treatment prevented MPTP‐induced behavioural, biochemical and neurochemical alterations, and the addition of DHA increases Nec‐1s' neuroprotective impact. In addition, Nec‐1s and DHA significantly improve the survival of TH‐positive dopaminergic neurons and lower expression levels of the inflammatory cytokines, IL‐1β and TNF‐α. Furthermore, Nec‐1s dramatically reduced RIP‐1 expression, whereas DHA had little effect. Our research raises the possibility that neuroinflammatory signalling and acute MPTP‐induced necroptosis are both mediated by TNFR1‐driven RIP‐1 activity. In this study, RIP‐1 ablation through Nec‐1s and the addition of DHA showed a reduction in the levels of pro‐inflammatory and oxidative markers, as well as protection from MPTP‐driven dopaminergic degeneration and neurobehavioural changes, suggesting potential therapeutic applications. For a better understanding, additional research about the mechanism(s) behind Nec‐1s and DHA is required.
- 27 February 2023
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 37 (4) , 794-806
Anti‐oxidative and anti‐neuroinflammatory role of Necrostatin‐1s and docosahexaenoic acid in RIP‐1‐mediated neurotoxicity in MPTP‐induced Parkinson's disease model
Parkinson's disease (PD) is a neuromuscular ailment that affects people in their later years and causes both motor and non‐motor deficits. Receptor‐interacting protein‐1 (RIP‐1) is a critical participant in necroptotic cell death, possibly through an oxidant–antioxidant imbalance and cytokine cascade activation in PD pathogenesis. The present study examined the role of RIP‐1‐mediated necroptosis and neuroinflammation in the MPTP‐induced PD mouse model, as well as their protection by Necrostatin‐1s (an RIP signalling inhibitor), antioxidant DHA and their functional interaction. BALB/c mice were given acute MPTP therapy (4 injections of 15 mg/kg i.p. at 2‐h intervals) on day 1. After MPTP intoxication, Necrostatin‐1s (Nec‐1s; 8 mg/kg/day, i.p.) and DHA (300 mg/kg/day, p.o.) treatments were given once daily for 7 days. The Nec‐1s treatment prevented MPTP‐induced behavioural, biochemical and neurochemical alterations, and the addition of DHA increases Nec‐1s' neuroprotective impact. In addition, Nec‐1s and DHA significantly improve the survival of TH‐positive dopaminergic neurons and lower expression levels of the inflammatory cytokines, IL‐1β and TNF‐α. Furthermore, Nec‐1s dramatically reduced RIP‐1 expression, whereas DHA had little effect. Our research raises the possibility that neuroinflammatory signalling and acute MPTP‐induced necroptosis are both mediated by TNFR1‐driven RIP‐1 activity. In this study, RIP‐1 ablation through Nec‐1s and the addition of DHA showed a reduction in the levels of pro‐inflammatory and oxidative markers, as well as protection from MPTP‐driven dopaminergic degeneration and neurobehavioural changes, suggesting potential therapeutic applications. For a better understanding, additional research about the mechanism(s) behind Nec‐1s and DHA is required.